Thompson Siegel & Walmsley LLC Lowers Stake in Lantheus Holdings, Inc. $LNTH

Thompson Siegel & Walmsley LLC lowered its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 14.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 234,531 shares of the medical equipment provider’s stock after selling 39,663 shares during the quarter. Thompson Siegel & Walmsley LLC owned 0.35% of Lantheus worth $15,608,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Osterweis Capital Management Inc. purchased a new position in Lantheus during the second quarter valued at approximately $36,000. Hantz Financial Services Inc. lifted its holdings in Lantheus by 412.5% during the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 396 shares in the last quarter. Larson Financial Group LLC lifted its holdings in Lantheus by 324.5% during the fourth quarter. Larson Financial Group LLC now owns 658 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 503 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in Lantheus by 71.4% during the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 275 shares in the last quarter. Finally, Blue Trust Inc. lifted its holdings in Lantheus by 30.3% during the fourth quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock valued at $66,000 after purchasing an additional 230 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on LNTH. The Goldman Sachs Group reissued a “neutral” rating and issued a $94.00 target price on shares of Lantheus in a report on Thursday, May 7th. Citizens Jmp boosted their target price on shares of Lantheus from $85.00 to $115.00 and gave the stock a “market outperform” rating in a report on Friday, May 8th. William Blair restated an “outperform” rating on shares of Lantheus in a research report on Tuesday, March 17th. B. Riley Financial restated a “buy” rating on shares of Lantheus in a research report on Friday, May 1st. Finally, Truist Financial restated a “buy” rating and issued a $115.00 price target (up from $98.00) on shares of Lantheus in a research report on Monday, May 11th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $101.86.

Lantheus Stock Performance

LNTH stock opened at $99.30 on Monday. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $103.89. The stock has a market capitalization of $6.47 billion, a price-to-earnings ratio of 23.93 and a beta of -0.03. The firm’s fifty day simple moving average is $85.66 and its two-hundred day simple moving average is $73.49.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The business had revenue of $377.33 million for the quarter, compared to analysts’ expectations of $354.48 million. During the same quarter in the previous year, the business posted $1.53 earnings per share. The business’s revenue was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, analysts anticipate that Lantheus Holdings, Inc. will post 4.41 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.